focus -WSS

focus

author：explore 2025-09-30 18:58:45 - browse：6

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Diversity in medical illustrations gets boost from Chidiebere Ibe

WSS

2024 GOP presidential candidates spar over abortion in debate

Psilocybin's anti

Ending racial health disparities hinges on penalties, political will

Judge rejects Trump's request to move Stormy Daniels hush

In science, is the line between industry and academia shifting?

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

knowledge

focus

leisure time

Malaria cases in Florida and Texas: Here’s what you need to know

Winners, losers from Medicare’s list of drugs subject to price talks

Novavax promises a turnaround & Lilly roils the obesity market

Diversity in medical illustrations gets boost from Chidiebere Ibe

Medical leaders decry Supreme Court decision on affirmative action

Tocagen's brain cancer gene therapy trial continues. Investors worry

The cancer drug shortage isn’t new — and neither are the solutions

Ending racial health disparities hinges on penalties, political will

Novavax promises a turnaround & Lilly roils the obesity market

Study identifies new proteins linked to dementia risk 25 years later

knowledge

Driven by the pandemic, applicants flood public health schools

Psilocybin's anti

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Mass General totes up its waste in a move to tackle climate change

What AAP's gender

Appeals court upholds limits to abortion pill

Wikipedia

explore

entertainment

entertainment